Back to top
more

Abbott Laboratories (ABT)

(Delayed Data from NYSE)

$110.94 USD

110.94
7,458,602

+1.05 (0.96%)

Updated Aug 15, 2024 04:00 PM ET

After-Market: $110.95 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (99 out of 251)

Industry: Medical - Products

Better trading starts here.

Zacks News

Urmimala Biswas headshot

3 Medical Product Stocks Likely to Beat This Earnings Season

Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.

Abbott (ABT) Meets Q3 Earnings Estimates, Lowers EPS Guidance

We are optimistic about Abbott's (ABT) strong and consistent EPD and Medical Devices performance organically.

Abbott (ABT) Meets Q3 Earnings Estimates

Abbott (ABT) delivered earnings and revenue surprises of 0.00% and -0.23%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Can Structural Heart Strength Aid Abbott (ABT) Q3 Earnings?

Abbott (ABT) has been growing popular with developments in its flagship, market leading device for the treatment of mitral regurgitation, MitraClip.

Abbott Forms Alliance With Omada Health for Diabetes Care

Abbott (ABT) collaborates with Omada Health to revolutionize diabetes care by expanding technological access.

Can Balanced Segmental Growth Aid Abbott (ABT) Q3 Earnings?

Abbott (ABT) is steadily gaining prominence for developments in its flagship, sensor-based continuous glucose monitoring (CGM) system of FreeStyle Libre.

Abbott (ABT) Stock Sinks As Market Gains: What You Should Know

Abbott (ABT) closed the most recent trading day at $79.62, moving -0.65% from the previous trading session.

Abbott (ABT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Abbott (ABT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Axonics (AXNX) Upbeat on Results of Its ARTISAN-SNM Study

Axonics (AXNX) expects to improve performance on the positive outcome of the study.

Abbott (ABT) Gains But Lags Market: What You Should Know

Abbott (ABT) closed the most recent trading day at $81.97, moving +1.11% from the previous trading session.

Abbott (ABT) Gets FDA Nod for New Troponin-I Blood Test

The regulatory go-ahead for Abbott's (ABT) ARCHITECT STAT High Sensitivity Troponin-I blood test is a major stride forward in its commitment for detecting patients suspected of having a heart attack.

Medtronic Upbeat on Drug-Eluting Stents in Patients With DAPT

Medtronic's (MDT) DAPT study's robust data outcome is likely to aid as the therapy duration might prove to be a superior treatment option.

Abbott (ABT) Gets FDA Nod for Spinal Cord Stimulation System

Abbott (ABT) is upbeat about the latest clearance in its neuromodulation product portfolio.

Abbott (ABT) Stock Moves -0.24%: What You Should Know

Abbott (ABT) closed at $82.66 in the latest trading session, marking a -0.24% move from the prior day.

Urmimala Biswas headshot

CGM Devices Gain Steam, Set New Trend in Diabetes Management

The FDA authorization classifies the new type of CGM devices in class II and subjects these to certain criteria called special controls.

Abbott Receives European Nod for Pediatric Heart Devices

Abbott (ABT) aims to offer better treatment options for the most vulnerable patient population.

Abbott Partners With Sanofi to Upgrade Diabetes Management

Abbott (ABT) collaborates with Sanofi to revolutionize diabetes care through technological advancements.

Abbott (ABT) Dips More Than Broader Markets: What You Should Know

Abbott (ABT) closed at $83.36 in the latest trading session, marking a -1.08% move from the prior day.

Abbott's (ABT) FreeStyle Libre Gains Canadian Reimbursement

With this reimbursement approval, Abbott's (ABT) FreeStyle Libre becomes the first sensor-based glucose monitoring system to be listed by any provincial health plan in Canada.

Abbott Sees Hammer Chart Pattern: Time to Buy?

Abbott Laboratories has been struggling lately, but the selling pressure may be coming to an end soon.

Abbott (ABT) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Abbott (ABT) closed at $83.19, marking a -1.22% move from the previous day.

Abbott (ABT) Launches Pivotal Trial TRILUMINATE in the US

Given the lack of an alternative therapy to replace tricuspid regurgitation surgery, Abbott (ABT) should be at an advantage in this space.

Here's Why You Should Hold on to Thermo Fisher (TMO) for Now

Investors continue to be optimistic about Thermo Fisher's (TMO) performance.

5 Cancer-Fighting Stocks to Add to Your Portfolio

Cancer-fighting stocks receive a boost from advance research and development. These five stocks can add value to your portfolio.

Abbott (ABT) Outpaces Stock Market Gains: What You Should Know

Abbott (ABT) closed the most recent trading day at $84.22, moving +0.68% from the previous trading session.